Published in Vaccine on November 29, 2006
Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebolavirus Species. PLoS Pathog (2010) 2.18
Disease modeling for Ebola and Marburg viruses. Dis Model Mech (2009) 2.07
Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates. Proc Natl Acad Sci U S A (2013) 1.81
Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One (2008) 1.67
Progress in filovirus vaccine development: evaluating the potential for clinical use. Expert Rev Vaccines (2011) 1.62
Replication-deficient ebolavirus as a vaccine candidate. J Virol (2009) 1.32
Filovirus tropism: cellular molecules for viral entry. Front Microbiol (2012) 1.18
Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One (2009) 1.16
Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol (2013) 1.11
Use of the Syrian hamster as a new model of ebola virus disease and other viral hemorrhagic fevers. Viruses (2012) 1.04
Ebolavirus VP35 is a multifunctional virulence factor. Virulence (2010) 1.02
Discovery, synthesis, and biological evaluation of a novel group of selective inhibitors of filoviral entry. J Med Chem (2011) 0.95
Functional genomics reveals the induction of inflammatory response and metalloproteinase gene expression during lethal Ebola virus infection. J Virol (2011) 0.89
Ad35 and ad26 vaccine vectors induce potent and cross-reactive antibody and T-cell responses to multiple filovirus species. PLoS One (2012) 0.85
Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever. J Biomed Biotechnol (2011) 0.84
Experimental respiratory Marburg virus haemorrhagic fever infection in the common marmoset (Callithrix jacchus). Int J Exp Pathol (2013) 0.83
Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice. J Infect Dis (2015) 0.78
Ebola vaccines in clinical trial: The promising candidates. Hum Vaccin Immunother (2016) 0.77
Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection. Sci Rep (2016) 0.76
Molecular dynamics exploration of the binding mechanism and properties of single-walled carbon nanotube to WT and mutant VP35 FBP region of Ebola virus. J Biol Phys (2017) 0.75
Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J Infect Dis (2003) 3.15
Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A (2003) 2.18
Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis. Antimicrob Agents Chemother (2006) 1.34
Abating colon cancer polyposis by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc Natl Acad Sci U S A (2012) 1.30
Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus. Vaccine (2005) 1.27
Ebola and Marburg virus-like particles activate human myeloid dendritic cells. Virology (2004) 1.13
Dendritic cells generated in the presence of GM-CSF plus IL-15 prime potent CD8+ Tc1 responses in vivo. Eur J Immunol (2004) 1.12
Peptides identified through phage display direct immunogenic antigen to dendritic cells. J Immunol (2004) 1.06
Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis. Expert Rev Anti Infect Ther (2009) 0.99
Macrophages and chemokines as mediators of angiogenesis. Front Physiol (2013) 0.98
Key roles of dendritic cells in lung infection and improving anthrax vaccines. Trends Mol Med (2010) 0.91
Lipoteichoic acid-deficient Lactobacillus acidophilus regulates downstream signals. Immunotherapy (2011) 0.90
Microbiota impact on the epigenetic regulation of colorectal cancer. Trends Mol Med (2013) 0.90
Fibroblastic reticular cell infection by hemorrhagic fever viruses. Immunotherapy (2009) 0.90
Tailoring gut immune responses with lipoteichoic acid-deficient Lactobacillus acidophilus. Front Immunol (2013) 0.86
Induction of intestinal pro-inflammatory immune responses by lipoteichoic acid. J Inflamm (Lond) (2012) 0.85
Modulating intestinal immune responses by lipoteichoic acid-deficient Lactobacillus acidophilus. Immunotherapy (2012) 0.84
Microenvironmental impact on lung cell homeostasis and immunity during infection. Expert Rev Vaccines (2008) 0.84
Targeting aberrant colon cancer-specific DNA methylation with lipoteichoic acid-deficient Lactobacillus acidophilus. Gut Microbes (2012) 0.83
Reprogramming intestinal immunity is the answer to induced pathogenic inflammation. Immunotherapy (2011) 0.82
Colonic immune stimulation by targeted oral vaccine. PLoS One (2013) 0.81
MHC class II epitope nesting modulates dendritic cell function and improves generation of antigen-specific CD4 helper T cells. J Immunol (2011) 0.81
Microbial activation of gut dendritic cells and the control of mucosal immunity. J Interferon Cytokine Res (2013) 0.80
Fibroblastic reticular cells and their role in viral hemorrhagic fevers. Expert Rev Anti Infect Ther (2009) 0.78
Lactobacilli as natural enhancer of cellular immune response. Discov Med (2005) 0.77
New generation of oral mucosal vaccines targeting dendritic cells. Curr Opin Chem Biol (2013) 0.76
Mitigating colon cancer with a novel strain of Lactobacillus acidophilus: a (re-)balancing act. Immunotherapy (2012) 0.75